Float Short %

3.03

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

1.37

EPS Last/This Y

10.15

EPS This/Next Y

5.5

Price

14.08

Target Price

17.67

Analyst Recom

Performance Q

37.3

Upside

-6,266.4%

Beta

1.48

Ticker: NXTC

19 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-01-23	NXTC	11.9	N/A	N/A	0
2026-01-26	NXTC	12.4	N/A	N/A	0
2026-01-27	NXTC	11.12	N/A	N/A	0
2026-01-28	NXTC	10.83	N/A	N/A	0
2026-01-29	NXTC	10.43	N/A	N/A	0
2026-01-30	NXTC	10.94	N/A	N/A	0
2026-02-02	NXTC	10.91	N/A	N/A	0
2026-02-03	NXTC	11.16	N/A	N/A	0
2026-02-04	NXTC	11.96	N/A	N/A	0
2026-02-05	NXTC	11.09	N/A	N/A	0
2026-02-06	NXTC	11.13	N/A	N/A	0
2026-02-09	NXTC	11.89	N/A	N/A	0
2026-02-10	NXTC	12.32	N/A	N/A	0
2026-02-11	NXTC	12.35	N/A	N/A	0
2026-02-12	NXTC	13	N/A	N/A	0
2026-02-13	NXTC	13.03	N/A	N/A	0
2026-02-17	NXTC	12.91	N/A	N/A	0
2026-02-18	NXTC	13.12	N/A	N/A	0
2026-02-20	NXTC	14.05	N/A	N/A	0
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

19 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-01-23	NXTC	11.90	53.5	18.9	-13.73
2026-01-26	NXTC	12.20	53.5	10.5	-13.73
2026-01-27	NXTC	11.31	53.5	21.2	-13.73
2026-01-28	NXTC	10.74	53.5	18.2	-13.73
2026-01-29	NXTC	10.69	53.5	12.5	-13.73
2026-01-30	NXTC	10.94	53.5	5.4	-13.73
2026-02-02	NXTC	11.23	53.5	5.9	-13.73
2026-02-03	NXTC	11.38	53.5	6.2	-13.73
2026-02-04	NXTC	11.90	53.5	2.6	-13.73
2026-02-05	NXTC	11.37	53.5	19.5	-13.73
2026-02-06	NXTC	11.20	53.5	12.7	-13.73
2026-02-09	NXTC	11.81	53.5	2.9	-13.73
2026-02-10	NXTC	12.31	53.5	8.1	-13.73
2026-02-11	NXTC	12.40	53.5	11.2	-13.73
2026-02-12	NXTC	13.05	53.5	8.6	-13.73
2026-02-13	NXTC	13.12	53.5	11.6	-13.73
2026-02-17	NXTC	12.91	53.5	14.4	-13.73
2026-02-18	NXTC	13.07	53.5	10.7	-13.73
2026-02-19	NXTC	14.07	53.5	-	-13.73
2026-02-20	NXTC	14.08	53.5	-	-13.73
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

19 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-01-23	NXTC	0.00	7.18	1.71
2026-01-26	NXTC	0.00	7.18	1.71
2026-01-27	NXTC	0.00	7.18	1.71
2026-01-28	NXTC	0.00	7.18	2.55
2026-01-29	NXTC	0.00	7.18	2.55
2026-01-30	NXTC	0.00	7.18	2.55
2026-02-02	NXTC	0.00	7.18	2.55
2026-02-03	NXTC	0.00	7.18	3.08
2026-02-04	NXTC	0.00	7.18	3.08
2026-02-05	NXTC	0.00	7.18	3.08
2026-02-06	NXTC	0.00	7.18	3.08
2026-02-10	NXTC	0.00	8.49	3.08
2026-02-11	NXTC	0.00	8.49	3.03
2026-02-12	NXTC	0.00	8.49	3.03
2026-02-13	NXTC	0.00	8.49	3.03
2026-02-17	NXTC	0.00	4.62	3.03
2026-02-18	NXTC	0.00	4.62	3.03
2026-02-19	NXTC	0.00	4.62	3.03
2026-02-20	NXTC	0.00	4.62	3.03
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

19 items 1 of 1

Last Quarter Act. EPS

-3.22

Avg. EPS Est. Current Quarter

-2.29

Avg. EPS Est. Next Quarter

-1.85

Insider Transactions

Institutional Transactions

4.62

Beta

1.48

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

91.3

Max Drawdown 5-Year %

-98

Target Price

17.67

P/E

Forward P/E

PEG

P/S

P/B

1.55

P/Free Cash Flow

EPS

-24.19

Average EPS Est. Cur. Y

-13.73

EPS Next Y. (Est.)

-8.22

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

0.62

Return on Equity vs Sector %

-274.3

Return on Equity vs Industry %

-256.9

EPS 1 7Days Diff

0.6

EPS 1 30Days Diff

1.86

EBIT Estimation

NextCure, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 43

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fusion protein of LAIR-2, that is designed to block immune suppression mediated by LAIR-1; NC525, a novel LAIR-1 antibody that targets acute myeloid leukemia, blast cells, and leukemic stem cells; NC181 a humanized antibody targeting ApoE4 for the treatment of Alzheimer's disease; and NC605 an antibody that targets Siglec-15, as well as chronic bone diseases, such as osteoarthritis and non-union fractures. The company also develop SIM0505, a novel antibody-drug conjugate (ADC) targeting CDH6 (cadherin-6 or K-cadherin) for the treatment of solid tumors. NextCure, Inc. was incorporated in 2015 and is headquartered in Beltsville, Maryland.

stock quote shares NXTC – Nextcure Inc Stock Price stock today

news today NXTC – Nextcure Inc stock forecast ,stock prediction 2023 2024 2025

marketwatch NXTC – Nextcure Inc yahoo finance google finance

stock history NXTC – Nextcure Inc invest stock market

stock prices NXTC premarket after hours

ticker NXTC fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: NXTC

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y